Role of Amlodipine in Reduction of CIN

Early Phase 1Not Yet RecruitingNCT07291375

Minia University40 enrolled

Overview

The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Contrast-induced Nephropathy

Interventions

Calcium channel blockerDRUG

amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour

HydrationOTHER

before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3 Exclusion Criteria: * patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients

Outcomes

Primary Outcomes

measuring serum creatinine level

measuring serum creatinine level before the procedure and every day for 48 hours after

Time frame: baseline

Central Contacts

Andrew Shehata, Master

CONTACT

0201067820073 andrewlengouini.95@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.